Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special Drug Use Investigation (Retrospective) for Arixtra (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Next Previous
Trial Profile

Special Drug Use Investigation (Retrospective) for Arixtra (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 14 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 25 Jul 2014 Planned End Date changed from 1 Jul 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
  • 14 Jun 2013 Planned End Date changed from 1 Oct 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top